7. Novo Nordisk (NYSE:NVO)
Novo Nordisk (NYSE: NVO) takes the No. 7 spot among cheap stocks to buy for the next 10 years because it remains one of the most important pharmaceutical companies in the world, especially in diabetes care, obesity treatment, and rare disease therapies. Trading at $47.08, Novo Nordisk has become a household name among investors because of the global weight-loss drug boom. But the story is bigger than market hype. The company has been around since 1923, is headquartered in Denmark, and has spent decades building expertise in metabolic health. That long track record gives it credibility in one of the fastest-growing healthcare markets today.
On May 13, Novo Nordisk presented new data from the OASIS 4 clinical trial at the European Congress on Obesity 2026, and the results gave investors another reason to watch the stock closely. The trial focused on the oral Wegovy pill at a 25 mg dose. According to the findings, nearly one-third of participants were early responders, achieving 13.2% weight loss within the first four months and reaching an average of 21.6% by the end of the 64-week study. Even participants who did not meet the early-response criteria still achieved a clinically meaningful weight loss of 11.5%.
That matters because obesity treatment is not just about cosmetics or lifestyle branding. It is one of the biggest healthcare markets in the world because obesity is tied to diabetes, cardiovascular disease, mobility issues, and long-term healthcare costs. A successful oral weight-loss drug could expand access and convenience for patients who prefer pills over injections. In the pharmaceutical industry, convenience can be a major competitive advantage. If patients are more willing to start and stay on treatment, the addressable market can become significantly larger over time.
The OASIS 4 data also showed benefits beyond weight reduction. Nearly 80% of participants who entered the trial with poor physical function reported almost double the improvement in movement, standing, and daily activity compared with the placebo group. This is an important point because investors often focus only on percentage weight loss, but regulators, doctors, and patients also care about quality of life. If a treatment helps patients become more mobile and physically capable, it strengthens the overall medical and commercial case.
The safety profile was also consistent with the GLP-1 receptor agonist class, with most side effects described as mild to moderate gastrointestinal issues. That is significant because tolerability can influence real-world adoption. In a competitive obesity drug market, effectiveness alone is not enough. Patients and doctors also consider side effects, discontinuation rates, dosing convenience, insurance coverage, and long-term outcomes.
Novo Nordisk’s oral Wegovy pill also appeared favorable in comparative analyses against competitors such as orforglipron. The data suggested superior weight loss results and significantly lower odds of treatment discontinuation due to side effects. The oral 25 mg dose is currently FDA-approved and pending regulatory approval in other markets, which could expand Novo Nordisk’s opportunity in long-term weight management and cardiovascular risk reduction.
For investors searching for cheap healthcare stocks, long-term pharmaceutical stocks, and obesity drug stocks to buy, Novo Nordisk remains a major name to watch. The company is not risk-free, especially as competition intensifies and pricing questions remain. However, its brand strength, clinical pipeline, market leadership, and diabetes-obesity platform make it one of the more compelling long-term stocks on this list. Over the next decade, Novo Nordisk’s ability to defend and expand its GLP-1 franchise could determine whether NVO remains one of the strongest healthcare growth stories in the market.
Click next to see the following stock...
